SCHEMBL3584900

SCHEMBL3584900

COCCN1Cc2ccc(N)cc2NC1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA9 Q16790 2/20 0.43
PARP1 P09874 2/20 0.41
ALDH1A1 P00352 5/20 0.38
KDM4E B2RXH2 4/20 0.38
HSD17B10 Q99714 1/20 0.38
MAPK1 P28482 2/20 0.38
GAA P10253 2/20 0.37
MAPT P10636 2/20 0.37
GLA P06280 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
HPGD P15428 1/20 0.36
CA2 P00918 1/20 0.35
ADRA1B P35368 1/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
TRPV1 Q8NER1 2/20 0.35
BRD4 O60885 1/20 0.35
CREBBP Q92793 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3597379 0.89 BRD4 (0.41) CA9PARP1ALDH1A1KDM4EHSD17B10
SCHEMBL3584898 0.84 ALDH1A1 (0.39) CA9PARP1ALDH1A1KDM4EHSD17B10
SCHEMBL3600321 0.83 CA9 (0.47) CA9ALDH1A1KDM4EHPGDTRPV1
SCHEMBL3588326 0.82 DUT (0.40) CA9ALDH1A1KDM4EMAPK1GAA
SCHEMBL13545267 0.82 TRPV1 (0.40) ALDH1A1KDM4EHSD17B10MAPTTRPV1
SCHEMBL13077879 0.80 BRD4 (0.57) PARP1ALDH1A1KDM4EHSD17B10MAPK1
SCHEMBL31192602 0.80 BRD4 (0.57) PARP1ALDH1A1KDM4EHSD17B10MAPK1
SCHEMBL3607837 0.80 AKR1B1 (0.44) PARP1ALDH1A1GAAMAPTMEN1
SCHEMBL27790555 0.79 CA9 (0.49) CA9ALDH1A1KDM4EGAAMAPT
SCHEMBL3599751 0.76 BRD4 (0.59) CA9KDM4EGAAMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
EP-2128157-A1 HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2009-12-02 EP disclosed
CN-101589038-A Heterocyclidene-N-(aryl)acetamide derivative MOCHIDA PHARM CO LTD (JP) 2009-11-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE CCNY, CCND3, NSD3 CA9 1531/4885PARP1 1468/4885ALDH1A1 1904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.